Seattle Genetics rare cancer drug sails through accelerated approval

被引：7
|
作者：
DeFrancesco, Laura
机构：
[1] Senior Editor,
来源：
NATURE BIOTECHNOLOGY | 2011年 / 29卷 / 10期
关键词：
D O I：
10.1038/nbt1011-851
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：850 / 851
页数：2
相关论文
共 50 条
  • [1] Seattle Genetics rare cancer drug sails through accelerated approval
    Laura DeFrancesco
    Nature Biotechnology, 2011, 29 : 851 - 852
  • [2] A roadmap for accelerated drug approval in breast cancer?
    Perez-Garcia, Jose
    Cortes, Javier
    LANCET ONCOLOGY, 2012, 13 (09): : 850 - 851
  • [3] The Accelerated Drug Approval
    Novack, Gary D.
    OCULAR SURFACE, 2010, 8 (04): : 205 - 206
  • [4] Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
    Prowell, Tatiana M.
    Pazdur, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26): : 2438 - 2441
  • [5] LYMPHOMA DRUG RECEIVES ACCELERATED APPROVAL
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2011, 111 (11) : 24 - 24
  • [6] Accelerated Drug Approval and Health Inequality
    London, Alex John
    Kimmelman, Jonathan
    JAMA INTERNAL MEDICINE, 2016, 176 (07) : 883 - 884
  • [7] Seattle genetics seals two drug pacts
    不详
    CHEMICAL & ENGINEERING NEWS, 2007, 85 (03) : 34 - 34
  • [8] TIME TO APPROVAL OF NOVEL CANCER MEDICINES GRANTED ACCELERATED APPROVAL AND IMPLICATIONS FOR REFORM OF THE ACCELERATED APPROVAL PATHWAY
    Hwang, Thomas
    Tibau, Ariadna
    JOURNAL OF UROLOGY, 2024, 211 (05): : E941 - E941
  • [9] Accelerated drug approval: Meeting the ethical yardstick
    Andreoletti, Mattia
    Blasimme, Alessandro
    BIOETHICS, 2023, 37 (07) : 647 - 655
  • [10] Collateral damage from accelerated drug approval
    Ozaki, Akihiko
    Gonda, Kenji
    Kaneda, Yudai
    Tanimoto, Tetsuya
    NATURE, 2023, 622 (7982) : 242 - 242
12345